This antibody is capable of binding to the PRG-3 protein as well as inhibiting the growth of cells expressing the PRG-3 protein. The growth inhibitory activity is cytotoxic activity, such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.
Figure 1 The reactivity of a PRG-3 hybridoma culture supernatant to PRG-3/293T-REX cells.
The reactivity of the antibody contained in the hybridoma culture supernatant toward PRG3+/293 cells wherein the expression of PRG-3 was induced and PRG3-/293 cells wherein the expression of PRG-3 was not induced was compared by GeoMean values measured by flow cytometry.
Figure 2 The binding of the anti-PRG-3 monoclonal antibody to HepG2 cells.
The binding of the antibody to HepG2 cells at antibody concentrations of 10 μg/mL, 1 μg/mL, and 0.1 μg/mL was compared by GeoMean values measured by flow cytometry.
Figure 3 ADCC activity of the anti-PRG-3 antibody in the OF5-G8 cell line.
Figure 4 CDC activity of the anti-PRG-3 antibody in the OF5 cell line.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
There are currently no Customer reviews or questions for TAB-1060CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.